EUVIMEDОткрийте EUVIMED
Klinische Studie (Phase II)

Addition of ruxolitinib and decitabine to modified busulfan/cyclophosphamide conditioning regimen for prophylaxis relapse in high-risk acute myeloid leukemia: the phase 2 prospective study

Yujun Wei, Kun Qian, Ning Le, Lili Wang, Fei Li, Songhua Luan, Lu Wang, Xiangshu Jin, Bo Peng, Nan Wang, Liping Dou, Daihong Liu

Annals of Hematology · 2024

DOI: 10.1007/s00277-024-05972-w ↗

At a glance

Klinische Studie (Phase II) in Annals of Hematology, 2024. Written by Yujun Wei and 11 co-authors. Institution: School of Medicine, Nankai University, Tianjin, 300071, China. Major MEDLINE topics: Decitabine, Leukemia, Myeloid, Acute, Transplantation Conditioning, Busulfan. Cited 3 times so far (Crossref); 42 references. Funded by: National Natural Science Foundation of China, Beijing Natural Science Foundation of China, Beijing Nova Program.

РезюмеSubjectsБиблиографски данниCiteRelated studies

Abstract (original language)

Няма налично резюме.

Subjects

MeSH terms (MEDLINE)

DecitabineLeukemia, Myeloid, AcuteTransplantation ConditioningBusulfanCyclophosphamidePyrimidinesPyrazolesAntineoplastic Combined Chemotherapy ProtocolsNitrilesHematopoietic Stem Cell TransplantationHumansAdultMaleFemaleMiddle AgedProspective StudiesAdolescentYoung AdultChildGraft vs Host DiseaseRecurrence

Author keywords

Acute myeloid leukemiaAllogeneic hematopoietic stem cell transplantationConditioning regimenRelapse

Substances

DecitabineBusulfanCyclophosphamidePyrimidinesPyrazolesNitrilesruxolitinib

Authors and institutions

  • School of Medicine, Nankai University, Tianjin, 300071, China.
  • Chief Department of Hematology, The Fifth Medical Center of Chinese PLA General Hospital, Beijing, 100071, China.
  • Department of Hematology, The First Medical Center of Chinese PLA General Hospital, Beijing, 100853, China.
  • Chief Department of Hematology, The Fifth Medical Center of Chinese PLA General Hospital, Beijing, 100071, China. lipingruirui@163.com.
  • School of Medicine, Nankai University, Tianjin, 300071, China. daihongrm@163.com.
  • Chief Department of Hematology, The Fifth Medical Center of Chinese PLA General Hospital, Beijing, 100071, China. daihongrm@163.com.

Funding

  • National Natural Science Foundation of China
  • Beijing Natural Science Foundation of China
  • Beijing Nova Program
  • National Key Research and Development Program of China
  • Military medical support innovation and generate special program
  • Special Research Found for Health Protection

Cite

APA

Wei, Y., Qian, K., Le, N., Wang, L., Li, F., Luan, S., Wang, L., Jin, X., Peng, B., Wang, N., Dou, L., & Liu, D. (2024). Addition of ruxolitinib and decitabine to modified busulfan/cyclophosphamide conditioning regimen for prophylaxis relapse in high-risk acute myeloid leukemia: the phase 2 prospective study. Annals of Hematology. https://doi.org/10.1007/s00277-024-05972-w

Vancouver

Wei Y, Qian K, Le N, Wang L, Li F, Luan S, et al. Addition of ruxolitinib and decitabine to modified busulfan/cyclophosphamide conditioning regimen for prophylaxis relapse in high-risk acute myeloid leukemia: the phase 2 prospective study. Annals of Hematology. 2024. doi:10.1007/s00277-024-05972-w

BibTeX
@article{Wei2024,
  author = {Wei, Yujun and Qian, Kun and Le, Ning and Wang, Lili and Li, Fei and Luan, Songhua and Wang, Lu and Jin, Xiangshu and Peng, Bo and Wang, Nan and Dou, Liping and Liu, Daihong},
  title = {Addition of ruxolitinib and decitabine to modified busulfan/cyclophosphamide conditioning regimen for prophylaxis relapse in high-risk acute myeloid leukemia: the phase 2 prospective study},
  journal = {Annals of Hematology},
  year = {2024},
  doi = {10.1007/s00277-024-05972-w}
}
Start for free →